ArticleDiscover oncology2026
Hypomethylation of the PXR gene promoter drives its overexpression in cisplatin-resistant EOC.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Epithelial ovarian cancer (EOC) remains the most lethal gynecological malignancy, with prognosis limited by extensive resistance to platinum-based therapy. Although the pregnane X receptor (PXR) has been implicated in chemoresistance, the upstream drivers of its aberrant activation in resistant EOC remain unclear. Here, we integrated bioinformatics, clinical specimen analysis, and functional assays to clarify the role of PXR in malignant progression and cisplatin resistance. PXR is significantly overexpressed in ovarian cancer, particularly in cisplatin-resistant cases, and is associated with poor overall survival. In clinical tissues, PXR and its downstream efflux transporter, MDR1, are co-regulated, with their levels correlating with advanced disease and chemoresistance. We show that DNA hypomethylation in the PXR gene promoter region is a key upstream epigenetic event driving its aberrant activation. In cisplatin-resistant tumor tissues and cell lines (A2780/DDP), the PXR promoter is significantly hypomethylated, and methylation levels are inversely correlated with PXR expression. Further studies revealed that siRNA-mediated knockdown of PXR inhibited EOC cell migration, invasion, and proliferation and restored cisplatin sensitivity, accompanied by MDR1 downregulation. Together, these results define a novel epigenetic–transcriptional pathway—PXR promoter hypomethylation leading to PXR activation and subsequent MDR1 induction—that drives EOC progression and chemoresistance. This work broadens our understanding of PXR regulation, highlighting its upstream epigenetic control, and provides a rationale for considering PXR and its epigenetic status as prognostic biomarkers as well as potential therapeutic targets to overcome drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.